直接抗病毒药物时代肝移植后肝细胞癌生存的种族和民族差异缩小
研究基于美国器官共享联合网络登记数据,纳入2009至2020年 listed 和/或接受肝移植的肝细胞癌患者,按移植时间分为直接抗病毒药物(DAA)前时代(2009-2011年移植)和DAA时代(2015-2017年移植,随访至2020年)。结果显示DAA时代黑人患者移植后生存与白人患者相当,而DAA前时代黑人患者3年生存率低于白人(70.6% vs 80.1%,P<.001),多变量分析中DAA前时代黑人患者死亡风险高于白人(校正HR 1.53,95%CI 1.28-1.84),DAA时代死亡风险相当(校正HR 1.23,95%CI 0.99-1.52)。结论认为随着DAA治疗的可及,肝移植后生存的种族差异有所改善。
要点
- DAA前时代黑人肝细胞癌患者移植后3年生存率低于白人(70.6% vs 80.1%,P<.001)。
- DAA时代黑人患者移植后生存与白人相当(82.1% vs 85.5%,P=.16)。
- DAA前时代黑人患者死亡风险高于白人(校正HR 1.53,95%CI 1.28-1.84),DAA时代相当(校正HR 1.23,95%CI 0.99-1.52)。
核心结论
- 随着DAA治疗的可及,肝移植后生存的种族差异有所改善。
研究设计与样本
- 基于美国器官共享联合网络登记数据的回顾性队列研究,纳入2009至2020年 listed 和/或接受肝移植的肝细胞癌患者。
- 按移植时间分为DAA前时代(2009-2011年移植)和DAA时代(2015-2017年移植,随访至2020年)。
主要发现
- DAA时代白人和西班牙裔患者因HCV相关肝细胞癌的年度等待名单新增显著减少,黑人患者无变化(P=.14)。
- DAA前时代黑人患者3年生存率低于白人(70.6% vs 80.1%,P<.001),DAA时代相当(82.1% vs 85.5%,P=.16)。
- 多变量分析中,DAA前时代黑人患者死亡风险高于白人(校正HR 1.53,95%CI 1.28-1.84),DAA时代死亡风险相当(校正HR 1.23,95%CI 0.99-1.52)。
- 黑人患者分层分析中,DAA前时代HCV相关肝细胞癌死亡风险增高(校正HR 2.86,95%CI 1.50-5.43),DAA时代降低(校正HR 1.34,95%CI 0.78-2.30)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Black patients with hepatocellular cancer (HCC), often attributed to hepatitis C virus (HCV) infection, have suboptimal survival following liver transplant (LT). We evaluated the impact of direct-acting antiviral (DAA) availability on racial and ethnic disparities in wait list burden post-LT survival for candidates with HCC. METHODS: Using the United Network for Organ Sharing registry, we identified patients with HCC who were listed and/or underwent LT from 2009 to 2020. Based on date of LT, patients were categorized into 2 era-based cohorts: the pre-DAA era (LT between 2009 and 2011) and DAA era (LT between 2015 and 2017, with follow-up through 2020). Kaplan-Meier and Cox proportional hazards analyses were used to compare post-LT survival, stratified by era and race and ethnicity. RESULTS: Annual wait list additions for HCV-related HCC decreased significantly in White and Hispanic patients during the DAA era, with no change (P = .14) in Black patients. Black patients had lower 3-year survival than White patients in the pre-DAA era (70.6% vs 80.1%, respectively; P < .001) but comparable survival in the DAA era (82.1% vs 85.5%, respectively; P = .16). 0n multivariable analysis, Black patients in the pre-DAA era had a 53% higher risk (adjusted hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.28-1.84), for mortality than White patients, but mortality was comparable in the DAA era (adjusted HR, 1.23; 95% CI, 0.99-1.52). In a stratified analysis in Black patients, HCV-related HCC carried more than a 2-fold higher risk of mortality in the pre-DAA era (adjusted HR, 2.86; 95% CI, 1.50-5.43), which was reduced in the DAA era (adjusted HR, 1.34; 95% CI, 0.78-2.30). CONCLUSIONS: With the availability of DAA therapy, racial disparities in post-LT survival have improved.
引用
- Shaikh A, Goli K, Lee TH, et al. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2022. PMID: 36521738. doi:10.1016/j.cgh.2022.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。